MENU

Can Turning Point Brands (TPB) Stock Reach $120?

a manufacturer of tobacco products

Industry: #Tobacco
A.I.Advisor
published price charts
A.I.Advisor
Nov 09, 2026

Can Turning Point Brands (TPB) Stock Reach $120?

Key Takeaways

  • The central target of $120 is the arithmetic mean of six current analyst price targets, rounded from roughly $118.50, spanning a wide range from $90 to $140.
  • With shares trading near $63 in early November 2026, reaching $120 would require an upside of roughly 90%, a very large move.
  • The target sits well below the stock's 52-week high of $146.90, reflecting how far shares have fallen since February 2026.
  • The strongest support comes from the nicotine-pouch (Modern Oral) business, where the FRE and ALP brands are growing rapidly and now generate about 49% of revenue.
  • The biggest risks are compressed margins from heavy marketing investment, a 41% year-over-year decline in adjusted EBITDA, and weakness in the legacy Zig-Zag business.
  • The company ended the third quarter with $251 million in cash and repurchased $10 million of stock, supporting its balance sheet.
  • For more context on this ticker, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
  • Investors looking for automated market analysis can also explore Trending AI Robots.

Analyst Price Targets and Consensus View

Turning Point Brands, Inc. (TPB) is a consumer products company that manufactures and distributes the Zig-Zag rolling-paper brand, Stoker's moist snuff and loose-leaf tobacco, and the FRE and ALP nicotine-pouch brands. The $120 central target reflects six verified analyst price targets, which range from a low of $90 to a high of $140. That spread alone signals meaningful disagreement about how quickly the company's strategic investments will translate into profitability.

Individual targets include Oppenheimer's $90 (a notable cut from $130 in September 2026), Alliance Global Partners' $115, BTIG's $116, and Needham's $125, which accompanied an upgrade to Buy from Hold. Views differ because analysts weigh the rapid revenue growth in nicotine pouches against the near-term earnings drag from higher sales and marketing spending. The average of all six targets is about $118.50, which rounds to a $120 reference point for this analysis. It is not an official published consensus, and it is not a guarantee of where the stock will trade.

Current Market Position and Path Toward the Target

Shares traded near $63 in early November 2026, after a steep decline from a February 2026 peak of $146.90. Moving to $120 would represent roughly a 90% advance, which is a very large move by any standard. In effect, the stock would need to retrace most of its 2026 losses while still remaining below its record high.

The path would likely depend on whether the company can demonstrate that its heavy investment in distribution and marketing is converting into durable, higher-margin revenue. Third-quarter results showed net sales up 27% year over year to about $151 million, but adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) fell 41% to $18 million as spending rose. A sustained recovery in profitability, rather than top-line growth alone, is central to any meaningful re-rating.

What Could Support a Move Toward the Target

The primary driver is the Modern Oral segment. Nicotine-pouch net sales rose 103% year over year to $74 million, and the segment now accounts for 49% of consolidated revenue, up from 31% a year earlier. Management expects to increase its chain store count by more than 70% during 2026 and plans to begin U.S. manufacturing in 2027, a move that could improve long-term margins.

Other supportive factors include a healthy balance sheet, with $251 million in cash and modest net debt, disciplined share repurchases, and a reaffirmed full-year outlook calling for $330 million to $350 million in Modern Oral gross sales and $70 million to $80 million in adjusted EBITDA. If margin expansion follows the distribution build-out, analysts' higher targets could look more attainable.

What Could Prevent the Target From Being Reached

The most immediate obstacle is profitability. Adjusted EBITDA declined 41% year over year, and net income fell roughly 81% to $3.9 million, as selling, general, and administrative expenses surged 69%. The Zig-Zag segment is also shrinking, with sales down 15% to $37 million, reducing a historical source of cash flow that funds the Modern Oral build-out.

Beyond operations, regulatory risk remains significant. Domestic manufacturing is tied to FDA review of the company's PMTA (premarket tobacco product application), and the broader nicotine-pouch category faces intense competition and possible regulatory scrutiny. A failure to translate distribution gains into margin improvement, or any delay in manufacturing plans, could keep the stock well below the $120 target.

Technical Levels and Market Structure

The stock's technical profile has weakened sharply. After peaking near $146.90 in February 2026, shares have fallen through prior support and now trade closer to the lower end of their 52-week range of roughly $54 to $147. The $120 target sits in a zone that previously acted as support during the stock's earlier advance, so regaining it would require a decisive break back above intervening resistance levels. The psychological $100 level also represents a notable hurdle on any recovery path.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a 12-month research horizon, though individual assumptions vary. Investors should watch quarterly earnings, updates on the FRE and ALP chain-store rollout, any changes to Modern Oral guidance, and progress on the FDA PMTA process for domestic manufacturing. Margins and adjusted EBITDA trajectory, along with the stabilization of Zig-Zag sales, will be the clearest signals of whether the business can support a higher valuation.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like Turning Point Brands, such tools can help traders spot shifting trends, monitor positions, and identify opportunities more efficiently than manual review. Investors can use these signals alongside fundamental research to stay ahead of evolving market structure.

Final Assessment

The $120 target, derived from six analyst price targets averaging about $118.50, implies roughly 90% upside from a share price near $63. The bull case rests on explosive growth in the FRE and ALP nicotine-pouch brands, expanding chain distribution, and planned U.S. manufacturing. The bear case centers on compressed margins, a 41% drop in adjusted EBITDA, a declining Zig-Zag business, and regulatory uncertainty. With analyst targets spanning $90 to $140, conviction is far from uniform. Reaching $120 would require the market to reward a profitability inflection that has not yet fully materialized.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

TPB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TPB has been loosely correlated with PM. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if TPB jumps, then PM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TPB
1D Price
Change %
TPB100%
-2.93%
PM - TPB
37%
Loosely correlated
-1.26%
BTI - TPB
28%
Poorly correlated
-1.10%
MO - TPB
21%
Poorly correlated
+0.25%
UVV - TPB
18%
Poorly correlated
-2.27%
RYM - TPB
9%
Poorly correlated
-8.67%
More
Can Turning Point Brands (TPB) Stock Reach $120?